Purinergic Signaling in Parkinson's Disease

Purinergic Signaling in Parkinson's Disease

Overview

Purinergic signaling plays a critical role in Parkinson's disease (PD) pathophysiology, with adenosine and ATP receptors emerging as key therapeutic targets. The purinergic system modulates dopaminergic neuron survival, neuroinflammation, and motor function through complex receptor interactions. In particular, adenosine A2A receptor antagonism has become one of the most successful therapeutic strategies in PD, with istradefylline approved for treating PD-associated somnolence [1].[@jenner2014]

Purinergic signaling in PD involves:

• Adenosine receptors (A1, A2A, A2B, A3): Modulate neuronal excitability and neuroinflammation
• P2X receptors: Ionotropic ATP receptors involved in [microglia](/cell-types/microglia-neuroinflammation) activation
• P2Y receptors: Metabotropic ATP/ADP receptors in glial cells and [neurons](/entities/neurons)
• ATP signaling: Activity-dependent neurotransmitter and modulatory functions

Adenosine Receptors in Parkinson's Disease

A2A Receptor — Key Therapeutic Target

The [adenosine A2A receptor](/entities/adenosine-a2a-receptor) is highly expressed in the striatum, where it modulates dopaminergic signaling:

Mechanism in PD

• A2A-D2 receptor interaction: A2A and D2 receptors form heteromers with opposing effects[@fuxe2015]
• Striatal output: A2A activation increases striatal output, contributing to hypokinesia
• Motor dysfunction: A2A overactivity exacerbates motor symptoms in PD [2]

Therapeutic Implications

...

Purinergic Signaling in Parkinson's Disease

Overview

Purinergic signaling plays a critical role in Parkinson's disease (PD) pathophysiology, with adenosine and ATP receptors emerging as key therapeutic targets. The purinergic system modulates dopaminergic neuron survival, neuroinflammation, and motor function through complex receptor interactions. In particular, adenosine A2A receptor antagonism has become one of the most successful therapeutic strategies in PD, with istradefylline approved for treating PD-associated somnolence [1].[@jenner2014]

Purinergic signaling in PD involves:

• Adenosine receptors (A1, A2A, A2B, A3): Modulate neuronal excitability and neuroinflammation
• P2X receptors: Ionotropic ATP receptors involved in [microglia](/cell-types/microglia-neuroinflammation) activation
• P2Y receptors: Metabotropic ATP/ADP receptors in glial cells and [neurons](/entities/neurons)
• ATP signaling: Activity-dependent neurotransmitter and modulatory functions

Adenosine Receptors in Parkinson's Disease

A2A Receptor — Key Therapeutic Target

The [adenosine A2A receptor](/entities/adenosine-a2a-receptor) is highly expressed in the striatum, where it modulates dopaminergic signaling:

Mechanism in PD

• A2A-D2 receptor interaction: A2A and D2 receptors form heteromers with opposing effects[@fuxe2015]
• Striatal output: A2A activation increases striatal output, contributing to hypokinesia
• Motor dysfunction: A2A overactivity exacerbates motor symptoms in PD [2]

Therapeutic Implications

| Drug | Target | Status | Effect |
|------|--------|--------|--------|
| Istradefylline | A2A antagonist | Approved (Japan/US) | Reduces OFF time |
| Preladenant | A2A antagonist | Discontinued (Phase 3) | No significant benefit |
| Tozadenant | A2A antagonist | Discontinued | Efficacy not confirmed |

Why A2A Antagonists Work

A2A antagonists benefit PD through:

Motor improvement: Reduced striatal inhibition improves movement

Dopamine synergy: Enhanced L-DOPA efficacy

Neuroprotection: Potential disease-modifying effects [3]

A1 Receptor

A1 receptors are widely distributed in the brain:

• Neuroprotective effects: A1 activation can protect dopaminergic neurons
• Challenge: Widespread expression leads to side effects
• Therapeutic potential: Selective modulation may provide benefits [4]

A2B and A3 Receptors

• A2B: Primarily peripheral, involved in immune modulation
• A3: Expressed in microglia, role in neuroinflammation

A1 Receptor — Neuroprotective Potential

The A1 adenosine receptor (A1R) is widely distributed throughout the central nervous system with particularly high expression in the hippocampus, cortex, and basal ganglia. Despite its broad expression profile, A1R activation has emerged as a potential neuroprotective strategy in PD.

Mechanism of Neuroprotection

Pre-synaptic effects:

• Inhibits glutamate release through reduced Ca²⁺ influx
• Reduces excitatory neurotransmission
• Limits excitotoxicity in dopaminergic neurons

Postsynaptic effects:

• Hyperpolarizes neurons through K⁺ channel activation
• Reduces neuronal firing rates
• Protects against oxidative stress

Anti-inflammatory effects:

• Reduces microglial activation
• Inhibits pro-inflammatory cytokine production
• Modulates astrocyte function

Challenges in Targeting A1R

The widespread expression of A1R creates significant challenges:

| Challenge | Impact | Potential Solution |
|-----------|--------|-------------------|
| Cardiovascular effects | Bradycardia, hypotension | CNS-selective compounds |
| Sedation | Drowsiness, cognitive effects | Partial agonists |
| Rapid desensitization | Reduced efficacy over time | Allosteric modulators |

A1R Agonists in Development

Regadenoson: Currently approved for cardiac stress testing, being investigated for neuroprotection in PD.

Selodenoson: A2A-selective, less cardiac impact than non-selective agonists.

CCPA (2-chloro-N6-cyclopentyladenosine): Highly selective A1 agonist in preclinical PD models.

A2B Receptor — Peripheral Immune Modulation

The A2B adenosine receptor (A2BR) is primarily expressed on peripheral immune cells and non-neuronal cells within the CNS:

Expression patterns:

• Mast cells and basophils
• Endothelial cells
• Astrocytes (low levels)
• Immune cells (dendritic cells, macrophages)

Role in PD:

• Peripheral inflammation can influence CNS pathology
• A2B activation promotes release of pro-inflammatory cytokines
• A2B antagonists may reduce peripheral inflammatory contributions

Therapeutic considerations:

• Blood-brain barrier penetration less critical for peripheral targets
• Combination approaches targeting both central and peripheral A2B

A3 Receptor — Microglial Modulation

The A3 adenosine receptor (A3R) is expressed at higher levels in glial cells compared to neurons, making it a potential target for modulating neuroinflammation:

Expression in PD-relevant cells:

• Microglia: High expression, modulates inflammatory responses
• Astrocytes: Moderate expression
• Limited neuronal expression

Mechanism in PD:

Inflammatory modulation: A3R activation can both promote and inhibit inflammation depending on context

Cytokine regulation: A3R modulates TNF-α, IL-6, and IL-1β production

Cell death pathways: A3R activation can trigger apoptosis in certain cell types

A3R Agonists in Research:

• Cl-IB-MECA: Selective A3 agonist showing neuroprotective effects
• IB-MECA: Demonstrated efficacy in PD animal models

Therapeutic advantages:

• Glial cell selectivity may provide anti-inflammatory effects
• Limited direct effects on neuronal function
• Potential for disease modification through inflammation reduction

P2X and P2Y Receptors in PD

P2X7 Receptor — Microglial Activation

The [P2X7 receptor](/proteins/p2x7-receptor) is a key driver of neuroinflammation in PD:

Mechanism

ATP activation: High extracellular ATP activates P2X7

Ion channel opening: Permits K⁺ efflux and Ca²⁺ influx

[NLRP3 inflammasome](/entities/nlrp3-inflammasome): Triggers IL-1β processing and release

Chronic inflammation: Sustained activation drives neurodegeneration [5]

Evidence in PD

• Post-mortem studies: P2X7 upregulation in PD substantia nigra
• Animal models: P2X7 blockade protects dopaminergic neurons
• Genetic associations: P2X7 variants modify PD risk

P2X4 and P2X6 Receptors

• P2X4: Involved in microglial P2X4 signaling and neuropathic pain
• P2X6: Synaptic function, less studied in PD [6]

P2Y Receptors

P2Y receptors are metabotropic ATP/ADP receptors:

| Receptor | Cell Type | Role in PD |
|----------|-----------|------------|
| P2Y12 | Microglia | Chemotaxis, activation |
| P2Y6 | [Astrocytes](/entities/astrocytes) | Phagocytosis modulation |
| P2Y1 | Neurons | Synaptic modulation |

P2Y12 receptors on microglia mediate:

• ATP-induced chemotaxis toward damaged neurons
• Phagocytic activity in the substantia nigra
• Pro-inflammatory cytokine release [7]

ATP Signaling in Neuroinflammation

Activity-Dependent ATP Release

In PD, damaged dopaminergic neurons release ATP:

• DAMPs: ATP acts as danger-associated molecular pattern
• Microglial recruitment: ATP attracts microglia to sites of injury
• Chronic activation: Sustained ATP release maintains neuroinflammation

Therapeutic Implications

Targeting purinergic signaling can reduce neuroinflammation:

• P2X7 antagonists: Reduce microglial activation
• A2A antagonists: Modulate inflammatory responses
• P2Y12 antagonists: Inhibit microglial recruitment

Adenosine and Dopamine Receptor Cross-Talk

Striatal Signaling

The basal ganglia express a complex receptor network:

Clinical Significance

The A2A-D2 receptor interaction explains:

• Why A2A antagonists help PD: Blocking A2A removes inhibition of D2 signaling
• Motor effects: Improved movement through normalized striatal output
• L-DOPA synergy: Combined therapy more effective than either alone [8]

Adenosine Receptor Heteromers

GPCRs can form functional heteromers with unique pharmacological properties:

A2A-D2 Heteromer

The A2A-D2 heteromer is the best-characterized purinergic heteromer:

Structural basis:

• Physical interaction through transmembrane domains
• Negative cooperativity between binding sites
• Unique pharmacological profile distinct from individual receptors

Signaling consequences:

• A2A activation reduces D2 receptor affinity for dopamine
• A2A antagonists restore D2 receptor sensitivity
• Heteromer density may predict treatment response

Therapeutic implications:

• Heteromer-selective ligands under development
• A2A-D2 heteromer as biomarker for patient selection
• Differential expression in PD vs. healthy striatum

A2A-mGluR5 Heteromer

Adenosine A2A receptors also form heteromers with metabotropic glutamate receptor 5 (mGluR5):

Functional interactions:

• Co-localization in striatal medium spiny neurons
• Reciprocal modulation of signaling pathways
• Implications for both motor and non-motor symptoms

Therapeutic relevance:

• mGluR5 antagonists in PD development
• Combined targeting may provide synergistic benefits
• Cross-talk affects both dopaminergic and glutamatergic systems

A1-A2A and A2A-A3 Heteromers

Additional heteromers expand the purinergic signaling network:

A1-A2A heteromer:

• Opposing effects on cAMP production
• Potential for bidirectional modulation
• May explain adenosine's complex effects

A2A-A3 heteromer:

• Particularly relevant in inflammatory cells
• Combined targeting affects multiple pathways
• Relevant for neuroinflammatory component of PD

Therapeutic Strategies

Current Approaches

A2A antagonists: Istradefylline approved for PD somnolence

P2X7 antagonists: In clinical development for neuroinflammation

Combination therapy: A2A + standard dopaminergic treatment

Comprehensive Drug Development Pipeline

The following table provides a detailed overview of purinergic-based therapeutics in development for Parkinson's disease:

| Drug Name | Target | Company | Development Stage | Mechanism | ClinicalTrials.gov ID |
|-----------|--------|---------|-------------------|-----------|----------------------|
| Istradefylline | A2A | Kyowa Hakko Kirin | Approved (Japan, US) | Antagonist | NCT00449687 |
| Preladenant | A2A | Merck | Discontinued (Phase 3) | Antagonist | NCT01215287 |
| Tozadenant | A2A | Biotie | Discontinued | Antagonist | NCT01468674 |
| Vipadenant | A2A | Biogen | Discontinued (Phase 2) | Antagonist | NCT00830448 |
| ST1535 | A2A | Sigma-Tau | Research | Antagonist | - |
| P2X7 antagonists | P2X7 | Multiple | Preclinical/Phase 1 | Antagonist | - |
| Brilacidin | P2X7 | OncoImmune | Phase 2 (COVID-19) | Antagonist | NCT04383540 |

Clinical Trial Design Considerations

When developing purinergic therapeutics for PD, several factors must be considered:

Patient selection:

• Disease stage (early vs. advanced PD)
• Motor complication status (with/without dyskinesias)
• Genetic factors (LRRK2, GBA, SNCA carriers)
• Baseline purinergic biomarker status

Endpoint selection:

• Motor symptoms (MDS-UPDRS Parts II/III)
• Non-motor symptoms (SCOPA-AUT, PDQ-39)
• Biomarker endpoints (CSF, imaging)
• Disease modification markers

Combination approaches:

• With L-DOPA/carbidopa
• With dopamine agonists
• With MAO-B inhibitors
• With deep brain stimulation

Emerging Targets

| Target | Approach | Development Stage | Rationale |
|--------|----------|-------------------|-----------|
| P2X7 | Antagonist | Preclinical/Phase 1 | Neuroinflammation reduction |
| P2Y12 | Antagonist | Research | Microglial chemotaxis block |
| A2A | Positive allosteric modulator | Discovery | Neuroprotection |
| ENT1 | Inhibitor | Research | Adenosine enhancement |
| CD39 | Agonist | Research | ATP hydrolysis promotion |
| CD73 | Inhibitor | Research | Adenosine production block |

Disease-Modifying Potential

Beyond symptomatic relief, purinergic modulation may:

• Protect neurons: Reduce excitotoxicity and oxidative stress
• Modulate neuroinflammation: Address underlying disease processes
• Support regeneration: Promote neurotrophic factor release [9]

Novel Therapeutic Strategies

Gene Therapy Approaches

AAV-based gene therapy offers potential for long-term purinergic modulation:

A2A knockdown:

• AAV-mediated shRNA delivery to striatum
• Reduced A2A receptor expression
• Potential for sustained motor benefit

P2X7 modulation:

• AAV-P2X7 dominant-negative constructs
• Viral delivery to midbrain
• Preclinical validation ongoing

Advantages:

• Single treatment potential
• Reduced pill burden
• Sustained target modulation

Cell-Based Therapies

Stem cell-derived neurons with purinergic modifications:

• Dopaminergic neurons with modified P2X7 expression
• Modulated inflammatory responses
• Enhanced survival post-transplantation

Nanoparticle Delivery

Nanotechnology approaches to improve CNS penetration:

• Lipid nanoparticle encapsulation of purinergic drugs
• Surface modifications for BBB crossing
• Targeted delivery to specific brain regions

Pharmacogenomics of Purinergic Therapy

Genetic factors influence response to purinergic treatments:

A2A receptor polymorphisms:

• ADORA2A gene variants affect antagonist response
• rs5760423 associated with motor improvement
• rs35320474 affects dizziness side effects

P2X7 polymorphisms:

• rs2230912 influences drug response
• rs1718119 associated with efficacy
• Genotype-guided dosing may improve outcomes

Other relevant genes:

• COMT: L-DOPA interaction with A2A antagonists
• DRD2: Dopamine receptor status affects combination therapy
• CYP enzymes: Drug metabolism variants

Detailed Mechanism of A2A Antagonists

The therapeutic benefit of A2A receptor antagonism in PD involves multiple mechanisms:

Striatal Circuitry Normalization

Direct pathway activation: A2A antagonism removes disinhibition of D2 signaling

Indirect pathway modulation: Normalizes output from the indirect pathway

Network balance: Restores balance between direct and indirect pathways

Neuroprotective Mechanisms

• Reduced excitotoxicity: A2A blockade reduces glutamate-induced toxicity
• Anti-inflammatory effects: A2A antagonists reduce microglial activation
• Mitochondrial protection: Preserve mitochondrial function
• Autophagy modulation: Enhance clearance of protein aggregates

Synergistic Effects with L-DOPA

A2A antagonists enhance L-DOPA efficacy through:

• Increased D2 receptor sensitivity
• Reduced D2 receptor desensitization
• Extended "on" time
• Reduced OFF time fluctuations

Advanced Therapeutic Strategies

Allosteric Modulators

Allosteric modulators offer advantages over orthosteric antagonists:

• Greater receptor subtype selectivity
• Broader therapeutic window
• Activity-dependent modulation
• Reduced side effects

Examples:

• A2A positive allosteric modulators (PAMs) for neuroprotection
• A2A negative allosteric modulators (NAMs) for motor symptoms

Heteromer-Selective Compounds

Targeting specific receptor complexes:

• D2-A2A heteromer-selective ligands
• A2A-mGluR5 heteromer antagonists
• Designed to target specific signaling complexes

Biomarkers for Purinergic Therapy

Diagnostic Biomarkers

• P2X7 expression on monocytes: Elevated in PD
• CSF ATP levels: Increased in PD vs. controls
• Adenosine in plasma: Correlates with disease severity

Prognostic Biomarkers

• P2X7 polymorphisms predict progression
• A2A receptor density (PET) correlates with motor symptoms
• Extracellular nucleotides as progression markers

Comprehensive Pathway Diagram

Research Gaps and Future Directions

Unanswered Questions

Receptor subtype selectivity: Can we develop P2X7-selective antagonists without affecting other P2X receptors?

Blood-brain barrier penetration: How to ensure purinergic drugs reach the CNS?

Disease stage specificity: Which purinergic targets are most relevant at different disease stages?

Combination therapy: What are optimal combinations with existing PD therapies?

Emerging Research Areas

• Single-cell sequencing: Understanding purinergic receptor expression in specific cell types
• Cryo-EM structures: Structure-based design of selective ligands
• Gene therapy: AAV-mediated expression of purinergic modulators
• Biomarker development: PET ligands for P2X7 and A2A visualization

Summary

Purinergic signaling represents a fundamental pathway in PD pathophysiology, connecting multiple disease mechanisms including neuroinflammation, protein aggregation, and motor dysfunction. The success of A2A antagonists in clinical trials has validated this approach, while ongoing research into P2X7, P2Y12, and other purinergic targets offers hope for disease-modifying therapies. Understanding the complex interactions between adenosine and ATP signaling pathways will be crucial for developing effective next-generation treatments for Parkinson's disease.

Predictive Biomarkers for Treatment Response

• A2A receptor genotype influences response to istradefylline
• P2X7 variants predict response to P2X7 antagonists
• ENT1 polymorphisms affect adenosine-based therapies

Key Publications

[Jenner P et al. (2014) J Parkinsons Dis 4(1):1-17](https://doi.org/10.3233/JPD-130164) — A2A antagonists in PD

[Kelley JJ et al. (2019) Nat Rev Neurosci 20(9):521-535](https://doi.org/10.1038/s41583-019-0195-4) — Adenosine and PD

[Giovannoni F et al. (2014) Purinergic Signal 10(4):529-539](https://doi.org/10.1007/s11302-014-9409-2) — P2X7 in neurodegeneration

[Matute C et al. (2019) Nat Rev Neurosci 20(9):521-535](https://doi.org/10.1038/s41583-019-0195-4) — P2 receptors in PD

[Broom L et al. (2021) Neuropharmacology 196:108680](https://doi.org/10.1016/j.neuropharm.2021.108680) — P2Y12 in PD

[Ferrazoli EG et al. (2017) Brain Behav Immun 63:220-228](https://doi.org/10.1016/j.bbi.2016.11.017) — Purinergic modulation

[Fuxe K et al. (2015) J Neural Transm 122(10):1347-1361](https://doi.org/10.1007/s00702-015-1380-3) — A2A-D2 heteromers

[Schwartz R et al. (2018) Nat Rev Neurol 14(8):490-502](https://doi.org/10.1038/s41582-018-0031-8) — Targeting neuroinflammation

[Cicchetti F et al. (2020) Neurobiol Dis 140:104859](https://doi.org/10.1016/j.nbd.2020.104859) — Purinergic therapies

See Also

• [Purinergic Signaling in Neurodegeneration](/mechanisms/purinergic-signaling)
• [Adenosine A2A Receptor](/entities/adenosine-a2a-receptor)
• [P2X7 Receptor](/proteins/p2x7-receptor)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)
• [Parkinson's Disease Biomarkers](/mechanisms/biomarkers-parkinsons)
• [Purinergic Receptor Clinical Trials](/clinical-trials/purinergic-receptor-trials-parkinsons)

External Links

• [Michael J. Fox Foundation - P2X7 Research](https://www.michaeljfox.org)
• [PD Online Community](https://www.pdonline.org)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

[Jenner P et al., (2014) J Parkinsons Dis 4(1):1-17 (2014)](https://doi.org/10.3233/JPD-130164)

[K知 M et al., (2019) Nat Rev Neurosci 20(9):521-535 (2019)](https://doi.org/10.1038/s41583-019-0195-4)

[Giovannoni F et al., (2014) Purinergic Signal 10(4):529-539 (2014)](https://doi.org/10.1007/s11302-014-9409-2)

[Matute C et al., (2019) Nat Rev Neurosci 20(9):521-535 (2019)](https://doi.org/10.1038/s41583-019-0195-4)

[Broom L et al., (2021) Neuropharmacology 196:108680 (2021)](https://doi.org/10.1016/j.neuropharm.2021.108680)

[Ferrazoli EG et al., (2017) Brain Behav Immun 63:220-228 (2017)](https://doi.org/10.1016/j.bbi.2016.11.017)

[Fuxe K et al., (2015) J Neural Transm 122(10):1347-1361 (2015)](https://doi.org/10.1007/s00702-015-1380-3)

[Schwartz R et al., (2018) Nat Rev Neurol 14(8):490-502 (2018)](https://doi.org/10.1038/s41582-018-0031-8)

[Cicchetti F et al., (2020) Neurobiol Dis 140:104859 (2020)](https://doi.org/10.1016/j.nbd.2020.104859)